Abbott Beats on Q2 Profit and Raises Its 2026 Earnings Outlook

The pharmaceutical and medical-device company Abbott released its second-quarter 2026 results on Thursday, July 16, 2026. Reported sales grew 13% and comparable sales rose 4.8%. GAAP diluted earnings per share came in at $0.53 and adjusted diluted EPS at $1.31.

Abbott raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60 (from a previous $5.38 to $5.58) and reaffirmed comparable sales growth of 6.5% to 7.5%. The company returned $2.1 billion to shareholders in the quarter through dividends and share buybacks.

Abbott shares rose about 4% in Thursday trading after the results. The report is part of the US large-cap earnings season that shapes the overall mood of global markets.